Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.
about
Current Biochemical Monitoring and Risk Management of Immunosuppressive Therapy after TransplantationPharmacogenetics of posttransplant diabetes mellitus.Comprehensive review of post-organ transplant hematologic cancers.Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice.Updated Follow-Up of a Tolerance Protocol in HLA-identical Renal Transplant Pairs Given Donor Hematopoietic Stem Cells.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus
P2860
Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Differential risks for adverse ...... ion regimen: a national study.
@en
Differential risks for adverse ...... ion regimen: a national study.
@nl
type
label
Differential risks for adverse ...... ion regimen: a national study.
@en
Differential risks for adverse ...... ion regimen: a national study.
@nl
prefLabel
Differential risks for adverse ...... ion regimen: a national study.
@en
Differential risks for adverse ...... ion regimen: a national study.
@nl
P2093
P2860
P50
P356
P1476
Differential risks for adverse ...... sion regimen: a national study
@en
P2093
Daniel C Brennan
Dorry L Segev
Jiajing Chen
Kenneth B Schechtman
Krista L Lentine
Mark A Schnitzler
P2860
P304
P356
10.1111/TRI.12850
P577
2016-09-28T00:00:00Z